Clinical trials
catalyst calendar across sponsors →Studies where CBIO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 6 tracked-famous managers (Balyasny Asset Management L.P., MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, +1 more) · FINRA short interest 8.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 7 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNCT07335497Dose Escalation - Incidence and nature of dose-limiting toxicitiesNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: CR-001 | Locally Advanced / Metastatic Solid Tumors | 290 | Feb 2029 | ≤ 923 d | 2026-08-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19